Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 27;10(2):329-336.
doi: 10.4254/wjh.v10.i2.329.

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents

Giovanni Damiani  1 , Chiara Franchi  2 , Paolo Pigatto  2 , Andrea Altomare  2 , Alessia Pacifico  3 , Stephen Petrou  4 , Sebastiano Leone  5 , Maria Caterina Pace  6 , Marco Fiore  6
Affiliations

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents

Giovanni Damiani et al. World J Hepatol. .

Abstract

Aim: To evaluate the outcomes in biological treatment and quality of life of psoriatic patients with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) compared to pegylated interferon-2α plus ribavirin (P/R) therapy.

Methods: This is a retrospective study involving psoriatic patients in biological therapy who underwent anti-hepatitis C virus (HCV) treatment at the Department of Dermatology Galeazzi Orthopaedic Institute Milan, Italy from January 2010 to November 2017. The patients were divided into two groups: patients that underwent therapy with DAAs and patients that underwent HCV treatment with P/R. Patients were assessed by a dermatologist for psoriasis symptoms, collecting Psoriasis Area Severity Index (PASI) scores and the Dermatology Quality of Life Index (DLQI). PASI and DLQI scores were evaluated 24 wk after the end of HCV treatment and were assumed as an outcome of the progression of psoriasis. Switching to a different bDMARD was considered as an inadequate response to biological therapy. The dropout of HCV therapy and sustained virological response (SVR) were considered as outcomes of HCV therapy.

Results: Fifty-nine psoriatic patients in biological therapy underwent antiviral therapy for CHC. Of this, 27 patients were treated with DAAs and 32 with P/R. After 24 wk post treatment, the DLQI and the PASI scores were significantly lower (P < 0.001 and P < 0.005, respectively) in the DAAs group compared with P/R group. None of the patients in the DAAs group (0/27) compared to 8 patients of the P/R group (8/32) needed a shift in biological treatment.

Conclusion: DAAs seem to be more effective and safe than P/R in HCV-positive psoriatic patients on biological treatment. Fewer dermatological adverse events may be due to interferon-free therapy.

Keywords: Biological disease modifying drugs; Hepatitis C virus; New Direct-Acting Antiviral agents; Psoriasis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386:983–994. - PubMed
    1. Psoriasis. Media resources of the American Academy of Dermatology. Available from: https://www.aad.org/media/stats/conditions/psoriasis.
    1. Hepatitis C. Media centre of the World Health Organization; updated October 2017. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
    1. Viral Hepatitis. Division of Viral Hepatitis and National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention of the Centers for Disease Control and Prevention; updated: May 11, 2017. Available from: https://www.cdc.gov/hepatitis/statistics/index.htm.
    1. Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143:1559–1565. - PubMed